Harmony Biosciences (HRMY) vs Disc Medicine (IRON)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Harmony Biosciences (HRMY) has outperformed Disc Medicine (IRON) over the past year, gaining 50.4% versus a loss of 13.5%. Over five years, HRMY leads with a +0.5% price change compared with -45.5% for IRON. Disc Medicine is the larger company by market cap ($2.38 billion vs $2.35 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HRMY | IRON |
|---|---|---|
| Share price | $40.28 | $62.06 |
| Market cap | $2.35B | $2.38B |
| 1-day change | +1.72% | +2.12% |
| YTD return | +7.64% | -23.47% |
| 1-year return | +50.41% | -13.53% |
| 5-year return | +0.51% | -45.55% |
| P/E ratio (TTM) | 12.99 | — |
| Forward P/E | 5.75 | — |
| EPS (TTM) | $3.10 | $-6.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $868.45M | — |
| Revenue growth (YoY) | +21.51% | — |
| Net income (latest FY) | $158.69M | $-212.18M |
| Gross margin | 77.16% | — |
| Operating margin | 24.00% | — |
| Net margin | 18.27% | — |
| 52-week high | $43.49 | $99.50 |
| 52-week low | $25.52 | $40.00 |
| Distance from 52-week high | -7.38% | -37.63% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +18.27% | +66.24% |
| Average volume | 892.55K | 471.18K |
| Shares outstanding | 58.24M | 38.39M |
| Employees | 293 | 165 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HRMY has outperformed IRON by 63.9 percentage points over the past year.
About Harmony Biosciences
HRMY stock →Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
Health Care · Biotechnology: Pharmaceutical Preparations · 293 employees
About Disc Medicine
IRON stock →Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.
Health Care · Biotechnology: Pharmaceutical Preparations · 165 employees
HRMY vs IRON FAQ
Which is bigger, Harmony Biosciences or Disc Medicine?
Disc Medicine (IRON) is larger, with a market capitalization of $2.38B compared with $2.35B for Harmony Biosciences (HRMY).
Which stock has performed better over the past year, HRMY or IRON?
HRMY returned +50.41% over the past 12 months, compared with -13.53% for IRON (price return, excluding dividends). Past performance does not predict future results.
Are Harmony Biosciences and Disc Medicine in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.